Comparison of Biologicals in Treatment of Severe Asthma

Sponsor
Helsinki University Central Hospital
Study ID
NCT04158050
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a retrospective clinical study on adult patients (18 years or more) with biological therapy for severe asthma at the Helsinki University Central Hospital (HUCH). This is a real-life study with a broader patient population than in a randomized controlled trial. Omalizumab has been used for treatment of asthma in HUCH since January 2009, anti-IL5 therapies starting with mepolizumab since April 2016.

Key Dates

Start date
Jan 1, 2018
Status verified
Feb 2023
Primary completion
Oct 31, 2020
Completion
Oct 31, 2020

Study Design

Enrollment
64 participants (actual)

Arms

  • Arm: anti-IL5/IL5R-therapy group
    Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
  • Arm: anti-IgE-therapy group
    Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy

Primary Outcome Measure

Change in Number of Exacerbations of the Participants [ Time Frame: baseline (12 months before biologicals) and the latest (12 months after initiation of biologicals) ]

Related Studies